Oligonucleotide Drugs Process Development

Oligonucleotide drugs encompass a range of chemically synthesized nucleic acid modalities with different molecular structures, backbone chemistries, nucleotide modifications, and manufacturing requirements. These differences can influence synthesis efficiency, impurity profiles, purification behavior, product quality, and scale-up considerations. Oligonucleotide drugs process development therefore requires a process strategy tailored to the specific characteristics of each molecular modality. Protheragen provides Oligonucleotide Drugs Process Development services for different oligonucleotide modalities, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), phosphorodiamidate morpholino oligomers (PMOs), and CpG oligonucleotides.

Overview of Oligonucleotide Drugs Process Development

Oligonucleotide drug process development focuses on establishing manufacturing processes that can consistently produce oligonucleotide drug substances with the required quality attributes. Although many oligonucleotide drugs are manufactured using stepwise chemical synthesis, differences in sequence, backbone chemistry, sugar modifications, terminal groups, and molecular architecture can result in substantially different process requirements.

During development, key manufacturing operations may include solid-phase synthesis, cleavage and deprotection, purification, concentration, isolation, and final drug substance processing. The performance of these operations can influence product yield, purity, impurity clearance, and process reproducibility. Process development therefore involves evaluating the relationship between molecular characteristics, process conditions, impurity formation, purification performance, and final product quality.

Different oligonucleotide modalities may also require different development considerations. ASOs commonly contain backbone and sugar modifications, while siRNA programs involve two complementary strands and may include strand-specific modifications. PMOs have a distinct backbone chemistry, and CpG oligonucleotides may incorporate sequence-specific motifs and chemical modifications. Modality-specific process development helps address these differences while establishing scalable and reproducible manufacturing processes.

Fig.1 Chemical modification and formulation strategies for delivery of oligonucleotide drugs. (Seth PP, et al., 2019)

Our Services

Protheragen provides modality-specific process development support covering the key stages from synthesis through drug substance preparation.

Modality-specific Process Development Considerations

Key Parameters in Oligonucleotide Drugs Process Development

Process development parameters are selected according to the characteristics of the specific oligonucleotide drug candidate. Important areas may include:

Applications

Protheragen's oligonucleotide drugs process development services can support:

• Antisense oligonucleotides (ASOs)
• Small interfering RNAs (siRNAs)
• Phosphorodiamidate morpholino oligomers (PMOs)
• CpG oligonucleotides
• Chemically modified oligonucleotides
• Conjugated oligonucleotides
• Preclinical oligonucleotide candidates
• Clinical-stage oligonucleotide drug substances

Why Choose Protheragen

• Modality-specific Development

Protheragen develops process strategies according to the molecular and chemical characteristics of different oligonucleotide drug modalities rather than applying a single process model to all candidates.

• Integrated Process Development

Synthesis, cleavage and deprotection, purification, impurity control, analytical evaluation, and scale-up are considered as interconnected parts of the development process.

• Manufacturing-oriented Approach

Process development considers scalability, reproducibility, impurity control, and manufacturing requirements from an early stage to facilitate later drug substance production.

• Support Across Development Stages

Process development can be adapted to early research, preclinical, IND-enabling, clinical, and later-stage manufacturing programs according to project requirements.

Effective process development provides the foundation for reproducible oligonucleotide drug substance manufacturing. By tailoring synthesis, purification, impurity control, process characterization, and scale-up strategies to individual oligonucleotide modalities, Protheragen supports the progression of drug candidates from early process development toward clinical and manufacturing stages. Our Oligonucleotide Drugs Process Development services can be adapted to the molecular characteristics, development stage, and manufacturing objectives of each program, providing a structured pathway from modality-specific process development to integrated CMC and drug substance manufacturing. Contact us to discuss your oligonucleotide drug process development requirements and develop a manufacturing strategy tailored to your ASO, siRNA, PMO, CpG, or other oligonucleotide program.